{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:49:31Z","timestamp":1791578971210,"version":"4.3.4"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Acute leukemias with KMT2A rearrangements (KMT2Ar) or mutant NPM1 (NPM1m) have historically poor outcomes despite intensive therapy. Menin, a scaffold protein encoded by MEN1, is a critical cofactor for the leukemic transcriptional program in these subsets. Targeting the menin-KMT2A interaction emerged as an effective strategy, leading to the first approvals of menin inhibitors (revumenib and ziftomenib) for relapsed\/refractory disease. This review assesses the current evidence and future directions for menin inhibition in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).\n                    <jats:bold>Methods:<\/jats:bold>\n                    We systematically searched PubMed, clinical trial registries, and conference proceedings (2015\u20132025) for studies on menin inhibitors in AML\/ALL. Both peer-reviewed articles and pivotal trial data, including FDA labels and regulatory documents, were included. Key trials were appraised for bias using the Cochrane criteria, which indicated a high risk of bias due to single-arm designs and short follow-up.\n                    <jats:bold>Findings:<\/jats:bold>\n                    Menin inhibitors achieve CR or CRh in \u223c20%\u201325% of heavily pretreated KMT2Ar or NPM1m leukemia patients. Median remission duration is \u223c5\u20136 months, with over half of responders attaining minimal residual disease (MRD) negativity. Differentiation syndrome (DS) occurs in \u223c15% of patients and is generally reversible with corticosteroids. Menin inhibitors\u2019 class-specific toxicities include QTc prolongation (notable with revumenib) and require careful electrocardiographic monitoring. Acquired resistance arises in \u223c40% of relapsed cases via MEN1 point mutations (especially M327I and T349M) that interfere with drug binding. Next-generation menin inhibitors (e.g., bleximenib) retain activity against some resistant variants. In newly diagnosed older adults with NPM1m or KMT2Ar AML, triplet therapy with revumenib, venetoclax, and azacitidine yielded composite CR rates &gt;80% and MRD-negative remissions in nearly all responders. Early integration of menin inhibitors into frontline regimens and maintenance therapy is feasible, including use in pediatric patients \u22651 year old. Emerging AI-driven models (e.g., multimodal drug response predictors and optimal-transport embedding of flow cytometry data) show promise in guiding combination strategies and MRD assessment.\n                    <jats:bold>Interpretation:<\/jats:bold>\n                    Menin inhibitors represent a significant advance for genetically defined acute leukemias, safely delivering clinically meaningful responses in KMT2Ar and NPM1m cases. Ongoing phase 3 studies will clarify if there is a survival benefit and the optimal use. Integrating menin inhibitors with existing therapies, from low-intensity combinations in older adults to intensive chemotherapy backbones in fit patients, is driving unprecedented response rates. Continued research into resistance mechanisms and innovative AI-guided treatment personalization will be essential to extend remission durability. As menin inhibitors move into frontline and pediatric settings, and as maintenance therapy posttransplant, they are positioned to become a new pillar of precision hematology, potentially improving cure rates for high-risk acute leukemia subgroups.\n                  <\/jats:p>","DOI":"10.4103\/hemoncstem.hemoncstem-d-26-00007","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:00:11Z","timestamp":1791576011000},"page":"e0007","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Menin inhibitors in acute leukemia: Advances and future directions"],"prefix":"10.4103","volume":"19","author":[{"given":"Abdulrahman","family":"Nasiri","sequence":"first","affiliation":[{"name":"College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa F. Mohammed","family":"Saleh","sequence":"additional","affiliation":[{"name":"Department of Hematology, Stem Cell Transplantation, and Cellular Therapy, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansour","family":"Alfayez","sequence":"additional","affiliation":[{"name":"Department of Hematology, Stem Cell Transplantation, and Cellular Therapy, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Alkhaldi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Stem Cell Transplantation, and Cellular Therapy, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad El","family":"Fakih","sequence":"additional","affiliation":[{"name":"Department of Hematology, Stem Cell Transplantation, and Cellular Therapy, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[{"name":"Department of Hematology, Stem Cell Transplantation, and Cellular Therapy, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4]]},"reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"The Lancet"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/sj.leu.2404150","article-title":"The MLL recombinome of acute leukemias","volume":"20","author":"Meyer","year":"2006","journal-title":"Leukemia"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"R7-20261009","year":"2024"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2024-194384","article-title":"Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1200\/JCO-25-01694","article-title":"Ziftomenib in relapsed or refractory NPM1-mutated AML","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"R11-20261009","year":"2025"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/blood-2024-198218","article-title":"Ziftomenib combined with intensive induction (7+3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007","volume":"144","author":"Zeidan","year":"2024","journal-title":"Blood"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 results: first-in-human phase 1\/2 study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1182\/blood-2025-3429","article-title":"Camelot-2: a phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed acute myeloid leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy","volume":"146","author":"Jabbour","year":"2025","journal-title":"Blood"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12935-023-02877-y","article-title":"A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1","volume":"23","author":"Numata","year":"2023","journal-title":"Cancer Cell Int"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1182\/blood-2023-173149","article-title":"Covalent menin inhibitor Bmf-219 in patients with relapsed or refractory (R\/R) acute leukemia (AL): preliminary phase 1 data from the covalent-101 study","volume":"142","author":"Lancet","year":"2023","journal-title":"Blood"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3324\/haematol.2024.286537","article-title":"Complete remission of NUP98 fusion-positive acute myeloid leukemia with the covalent menin inhibitor BMF-219, icovamenib","volume":"110","author":"Carraway","year":"2025","journal-title":"Haematologica"},{"key":"R18-20261009","first-page":"13","article-title":"Therapeutic implications of menin inhibitors in the treatment of acute leukemia: a critical review","author":"Canichella","year":"2025","journal-title":"Diseases"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J Clin Oncol"},{"key":"R20-20261009","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/hematology.2025000755","article-title":"The promise of menin inhibitors: from approval to triplet regimens","volume":"2025","author":"Thakur","year":"2025","journal-title":"Hematology"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"R23-20261009","article-title":"Ziftomenib combined with venetoclax\/azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007","volume":"144: 2880","author":"Fathi","year":"2024","journal-title":"Blood"},{"key":"R24-20261009","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2023-190475","article-title":"Komet-008: a phase 1 study to determine the safety and tolerability of ziftomenib combinations for the treatment of KMT2A-rearranged or NPM1-mutant relapsed\/refractory acute myeloid leukemia","volume":"142","author":"Goldberg","year":"2023","journal-title":"Blood"},{"key":"R26-20261009","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"key":"R27-20261009","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"R28-20261009","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood-2024-208887","article-title":"Discerning the landscape of menin inhibitor resistance","volume":"144","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"key":"R29-20261009","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1016\/S2152-2650(23)01067-4","article-title":"AML-475 activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed\/refractory NPM1-mutated AML","volume":"23","author":"Erba","year":"2023","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"R30-20261009","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"key":"R31-20261009","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2023021105","article-title":"Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML","volume":"143","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"key":"R32-20261009","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1158\/2643-3230.BCD-24-0212","article-title":"Combination strategies with menin inhibitors for acute leukemia","volume":"6","author":"Issa","year":"2025","journal-title":"Blood Cancer Discov"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.hemoncstem-D-26-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:00:15Z","timestamp":1791576015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.hemoncstem-D-26-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/hemoncstem.hemoncstem-d-26-00007","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2026-02-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}